Psychedelic Medicine

A team of scientists has demonstrated a novel microencapsulation method designed to improve the absorption and bioavailability of CBD. Animal tests suggest the new method increases peak concentrations of CBD in the brain by 300% compared to CBD oil.

Surfing the wave of new research into medical uses for psychedelic compounds, the Icahn School of Medicine at Mount Sinai has launched a dedicated psychedelic center focusing on the study of MDMA and psilocybin for PTSD and other stress-related conditions.

For the first time in decades, a pilot study has explored the effects of MDMA therapy in couples within the framework of a robust clinical trial. Following on from ongoing research into MDMA-assisted therapy for PTSD, the results are promising.

A study into the effects of cannabis on driving in a real-world context has found CBD alone does not impair driving ability. The landmark finding promises to be invaluable in guiding road safety regulations as cannabis laws shift across the globe.

An exploratory study has found a single dose of the psychedelic psilocybin can reduce migraine frequency by 50 percent for a least two weeks. The preliminary trial was small but the promising findings suggest potential for psychedelics to treat migraines.

New research is showing how the psychedelic drug DMT can promote brain plasticity and induce formation of new neurons. The study presents evidence to suggest the hallucinogenic effects of the drug could be divorced from this neuron-generating mechanism.

A progressive wave of drug reforms have been passed by US voters, including four states legalizing recreational marijuana, one state decriminalizing natural psychedelics, and Oregon decriminalizing all drugs and legalizing psilocybin psychotherapy.

A new study is presenting the first published data from preliminary human trials investigating the effect of psilocybin-assisted psychotherapy to treat major depressive disorder (MDD). The incredibly positive results have been described as just a “taste of things to come” with larger a Phase 2 trial well underway.

Some people find their symptoms of OCD dramatically drop after smoking cannabis, according to a new study. The improvements may only be beneficial in the short-term however, and more research is needed to understand the long-term effect of cannabis use on OCD.

An incredible, first-of-its-kind trial testing the pain-killing properties of LSD microdoses has delivered the compelling suggestion that tiny, non-psychedelic doses of this infamous drug could serve as an effective analgesic.

A novel clinical trial is set to explore the subjective effects of combining LSD and MDMA. The primary goal is to investigate whether MDMA can reduce some negative mood effects seen with LSD and improve outcomes for psychedelic-assisted psychotherapy.

A new study, led by researchers from University College London, is offering some of the first robust evidence showing how CBD, a key compound in cannabis, increases cerebral blood flow in memory processing regions of the brain such as the hippocampus.